These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1168 related articles for article (PubMed ID: 10327070)

  • 21. Chemotherapy and pregnancy.
    Leslie KK
    Clin Obstet Gynecol; 2002 Mar; 45(1):153-64. PubMed ID: 11862066
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of multikinase inhibitors on caspase-independent cell death and DNA damage in HER2-overexpressing breast cancer cells.
    Seoane S; Montero JC; Ocaña A; Pandiella A
    J Natl Cancer Inst; 2010 Sep; 102(18):1432-46. PubMed ID: 20811002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
    Foroodi F; Duivenvoorden WC; Singh G
    Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
    Agus DB; Scher HI; Higgins B; Fox WD; Heller G; Fazzari M; Cordon-Cardo C; Golde DW
    Cancer Res; 1999 Oct; 59(19):4761-4. PubMed ID: 10519379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and planned clinical trials with trastuzumab (Herceptin).
    Baselga J
    Semin Oncol; 2000 Oct; 27(5 Suppl 9):27-32. PubMed ID: 11049054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M
    Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chemosensitivity test for 170 human breast carcinoma samples].
    He Z; Yuan J; Chen Z; Liu S; Shen Z; Fei H
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):531-4. PubMed ID: 10806759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
    Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
    Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER2/neu antisense targeting of human breast carcinoma.
    Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
    Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
    Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
    Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The immunocytokine scFv23/TNF targeting HER-2/neu induces synergistic cytotoxic effects with 5-fluorouracil in TNF-resistant pancreatic cancer cell lines.
    Lyu MA; Kurzrock R; Rosenblum MG
    Biochem Pharmacol; 2008 Feb; 75(4):836-46. PubMed ID: 18082672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Adjuvant chemotherapy for breast cancer and targeted therapies].
    Dufresne A; Bachelot T; Blay JY
    Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
    [No Abstract]   [Full Text] [Related]  

  • 38. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New combinations with Herceptin in metastatic breast cancer.
    Winer EP; Burstein HJ
    Oncology; 2001; 61 Suppl 2():50-7. PubMed ID: 11694788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.